# Apolipoproteins in Psoriasis: The Effect of Acitretin Treatment and UVB Phototherapy

## TL;DR

This study examines how apolipoproteins in psoriasis patients change with acitretin or UVB treatment, finding no significant changes in apolipoprotein profiles.

## Contribution

The study provides new insights into apolipoprotein profiles in psoriasis patients before and after treatment with acitretin or UVB.

## Key findings

- ApoA2, ApoC1, ApoD, ApoE, and ApoJ levels were higher in acitretin-treated patients before treatment compared to UVB-treated patients.
- The ApoA1/ApoA2 ratio was negatively associated with psoriasis severity before treatment.
- Neither acitretin nor UVB treatment significantly altered apolipoprotein profiles.

## Abstract

Background: Psoriasis is a chronic, multi-system inflammatory disease frequently associated with metabolic syndrome and lipid disturbances. Apolipoproteins, as essential regulators of lipid metabolism, may play a critical role in these metabolic abnormalities, potentially influencing disease severity and systemic inflammation. The aim of this study was to compare serum concentrations of chosen apolipoproteins in patients with psoriasis before and after treatment with acitretin or narrowband UVB (NB-UVB). Methods: This study was conducted on 39 patients with psoriasis. The concentration of nine apolipoproteins and C-reactive protein was quantified using the Bio-Plex Immunoassay Kit. Results: The serum concentrations of ApoA2, ApoC1, ApoD, ApoE, and ApoJ were higher in the acitretin group compared to the NB-UVB group before treatment, while the ApoA1/ApoA2 ratio was lower. We also observed a negative association between the Psoriasis Area and Severity Index (PASI) and ApoA1/ApoA2 ratio in the patients before the treatment. Conclusions: The results of this study confirm the presence of metabolic disturbances in psoriatic patients. The treatment with NB-UVB or acitretin did not cause any significant changes in the apolipoproteins profile. Thus, we found no detrimental impact of acitretin on the apolipoproteins profile, despite the observed rise in total cholesterol concentration after the treatment. Further research is needed to explore whether specific therapeutic approaches can modify these disturbances and potentially improve long-term cardiovascular outcomes in this population.